홈MCP워크벤치Skills
홈워크벤치알림마이페이지
Huagongshe 오픈 프로젝트:[email protected]AI 접속: llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.7.8
  1. 홈
  2. /화합물

Retrorsine

HCID 5281743
노트반응
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
480-54-6
표준 SMILES
C/C=C1/C[C@@H](C)[C@](O)(CO)C(=O)OCC2=CCN3CC[C@@H](OC1=O)[C@@H]23
InChIKey
BCJMNZRQJAVDLD-CQRYIUNCSA-N
분자식
C18H25NO6
평균 분자량
351.4 g/mol
단동위원소 질량
351.16818752

개요

Retrorsine is a macrolide.

이름 및 식별자

우선 이름
Retrorsine
IUPAC
(1R,4Z,6R,7S,17R)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione
영어명
RETRORSINE
분자식
C18H25NO6
분자량
351.39

이름 및 동의어

RETRORSINE480-54-6beta-Longilobinecis-Retronecic acid ester of retronecineXJ86XWL8IY12,18-Dihydroxy-senecionan-11,16-dioneSenecionan-11,16-dione, 12,18-dihydroxy-DTXSID6021242trans-15-Ethylidene-12beta-hydroxy-12alpha-hydroxymethyl-13beta-methylsenec-1-enineNSC-1076593-Ethylidene-3,4,5,6,9,11,13,14,14a,14b-decahydro-6-hydroxy-6-hydroxymethyl-5-methyl(1,6)dioxacyclododeca(2,3,4-gh)pyrrolizidine-2,7-dione(1R,4Z,6R,7S,17R)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione
이름 더 보기
Retrosineβ-LongilobineRETRORSINE(AS)Retrorsine 100 μg/mL in Watercis-retronecicacidesterofretronecine16-dione,12,18-dihydroxy-senecionan-1
(1R,4Z,6R,7S,17R)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-2,9-dioxa-14-azatricyclo(9.5.1.014,17)heptadec-11-ene-3,8-dioneRefChem:930688DTXCID501242610-403-9Retrorsin12,18-Dihydroxysenecionan-11,16-dioneRetrorcinePrestwick_562

물성

구조 계산 물성

XLogP
0.6
극성 표면적
96.3 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
7
회전 가능 결합 수
1
무거운 원자 수
25
형식 전하
0
복잡도
627

실험 및 물리화학적 성질

LogPlog Kow = -1.88 @ 25 °C /Estimated/
Color/FormColorless prisms
Solubility · 3건

Soluble in chloroform; slightly soluble in acetone, ethanol, water

Practically insoluble in ether.

In water, 3.08X10+4 mg/L @ 25 °C /Estimated/

DecompositionWhen heated to decomposition it emits toxic fumes of /nitrogen oxide/.
Melting Point212 °C
Vapor Pressure1.9X10-14 mm Hg @ 25 °C /Estimated/
Optical RotationMax absorption (water): 217 nm (epsilon= 201, 1%, 1 cm); specific optical rotation (chloroform): -61.4 deg @ 20 °C/D
Henry's Law ConstantHenry's Law constant = 1.3X10-12 atm-cu m/mol @ 25 °C /Estimated/
Stability/Shelf Life · 2건

Stability: stable at room temperature in closed containers: best stored under nitrogen -15 °C.

Volatility: low ; stable at room temperature in closed containers

Dissociation Constants

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 41 reports by companies from 3 notifications to the ECHA C&L Inventory.

유해성 정보

Special Reports · 2건

HEALTH HAZARDS INCLUDING CARCINOGENICITY OF PYRROLIZIDINE ALKALOIDS ARE REVIEWED. USE OF PYRROLIZIDINE ALKALOIDS FOR MEDICINAL OR OTHER PURPOSES PRESENTS SERIOUS HAZARDS.[SCHOENTAL R; HEALTH HAZARDS OF PYRROLIZIDINE ALKALOIDS: A SHORT REVIEW; TOXICOL LETT 10(4) 323 (1982)]

CHEMICAL STRUCTURES, TOXICITY, & METABOLISM OF PYRROLIZIDINE ALKALOIDS SUCH AS HELIOTRINE & RETRORSINE ARE REVIEWED.[MATTOCKS AR; TOXICITY AND METABOLISM OF SENECIO ALKALOIDS; PHYTOCHEM ECOL, PROC PHYTOCHEM SOC SYMP 179-200 (1972)]

Hazard Classes and CategoriesAcute Tox. 2 (100%)

안전 및 보호

Storage ConditionsFor long periods the substance is best stored under nitrogen at -15 °C.

독성 정보

Interactions · 3건

...Weanling Porton Wistar rats were given single doses of 30 mg/kg body weight retrorsine by stomach tube...with whole-body irradiation of 400 rads 100 days after dosing, in 31 rats... In 25 survivors, there were 5 hepatomas, 5 mammary tumors, 2 renal carcinomas and 1 case each of carcinoma of the liver with pulmonary metastases, carcinoma of the lung, carcinoma of the colon, hemangioendothelioma of the spleen, osteosarcoma of the humerus, leukemia and spindle-cell tumor of the neck... /no controls presented/

화학 및 산업

약리 정보

Mechanism of Action · 4건

The dehydropyrrolizine metabolites...react with water, DNA, and other cell components in vitro, and are cytotoxic. The bioactivation is mediated by a c-oxygenation, a reaction which proceeds very slowly in microsomes from neonates but which increases rapidly in microsomes obtained up to 5 days after birth.

Intragastric admin of 7 mg/kg retrorsine inhibited incorporation of labeled amino acids into rat liver and plasma proteins in vivo. The toxin affected the liver ribosomal aggregates, causing increases in proportion of monomers plus dimers. Incorporation of orotate into liver nuclear RNA was inhibited 1 hr after admin.

Two procedures were used to study the role of liver glutathione in acute toxicity of retrorsine in rats. Glutathione levels in rats were increased to about double that of controls by cysteine and to about 25% that of control by 2-chloroethanol. Acute LD50 of retrorsine (42 mg/kg) to rats is increased by pretreatment with cysteine to 83 mg/kg and decreased by pretreatment with 2-chloroethanol to 23 mg/kg. Two hr after admin of retrorsine (60 mg/kg) the levels of pyrrolic metabolites in the livers of animals pretreated with cysteine or c-chloroethanol are, respectively, about 60% and 200% those of rats given no pretreatment. By 24 hr, the glutathione concentration in livers of retrorsine-dosed rats is higher than those of corresponding controls. Treatment of rats with retrorsine (60 mg/kg) causes a fall in liver concentration of cytochrome p-450, 24 hr after dosing. This loss of cytochrome p-450 is increased in rats pretreated with chloroethanol.

The activation of the alkaloids by mixed-function oxidases leads to pyrrolic dehydro-alkaloids which are reactive alkylating agents. The liver necrosis results from binding of the metabolites with the liver cell. Some metabolites are released into the circulation and are believed to pass beyond the liver to the lung causing vascular lesions. The pyrrolic metabolites are cytotoxic and act on the hepatocytes and on the endothelium of blood vessels of the liver and lung. /pyrrolizidine alkaloids/

Biological Half-Life · 1건

Within a few hours, only a relatively small proportion of the administered dose remains in the body. Much of this is in the form of metabolites bound to tissue contents. A pyrrolizidine N-oxide disappeared from the serum after IV administration in animals, with initial half-lives of 3 -20 minutes. /pyrrolizidine alkaloids/

관련 반응

0건
반응 기록 만들기

현재 필터 조건에 해당하는 반응 기록이 없습니다.

화합물 노트

불러오는 중…

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

데이터베이스 식별자

CAS
480-54-6
PubChem CID
5281743
DTXSID
DTXSID6021242
ChEMBL
CHEMBL496894、CHEMBL520570
ChEBI
CHEBI:8822
UNII
XJ86XWL8IY
EC Number
610-403-9
Nikkaji
J12.337D
pKa = 6.01 /Estimated/
Other Experimental Properties · 2건

Readily hydrolyzed with alkali; reacts with oxidizing agents (slowly with atmospheric oxygen) to form dihydropyrrolizine and other derivatives.

Hydroxyl radical reaction rate constant = 2X10-10 cu cm/molec-sec @ 25 °C /Estimated/

물리화학적 성질

녹는점
208 · 208-211 °C (lit.)
끓는 점
485.2 °C · 485.2°C (rough estimate)
밀도
1.32 · 1.32±0.1 g/cm3 (20 ºC 760 Torr)
굴절률
1.51 · 1.5100 (estimate)
저장 조건
2 · 2-8°C
용해도
0.1 · DMSO: Slightly soluble: 0.1-1 mg/mlPBS (pH 7.2): Slightly soluble: 0.1-1 mg/ml
산도 계수 (pKa)
12 · 12.00±0.40(Predicted)
물리적 상태
Solid
색상
White to off-white
Merck
13 · 13,8253
주요 응용
음식 및 음료
InChI
InChI=1S/C18H25NO6/c1-3-12-8-11(2)18(23,10-20)17(22)24-9-13-4-6-19-7-5-14(15(13)19)25-16(12)21/h3-4,11,14-15,20,23H,5-10H2,1-2H3/b12-3-/t11-,14-,15-,18-/m1/s1
InChIKey
BCJMNZRQJAVDLD-VMOBWIEOSA-N
SMILES
N12CC=C3COC(=O)[C@@](O)(CO)[C@H](C)C/C(=C/C)/C(=O)O[C@@]([H])([C@]13[H])CC2
EPA
Retrorsine (480-54-6)

Although most of the toxic effects of retrorsine appear to be mediated via the very reactive metabolite dehydroretrorsine (retrorsine pyrrole), which is produced in the liver by the mixed-function oxidases, the toxicity of this alkaloid does not always relate directly to the activity of the enzymes. Pre-treatment with phenobarbital (pb) which increases the rate of in vitro microsomal production of pyrroles from retrorsine three-fold and that of n-oxides two-fold, protected male rats against retrorsine poisoning (ip Ld50's, 34 mg/kg body weight alone, 67 mg/kg body weight with pb) but increased its toxicity in female rats (ip LD50's, 153 mg/kg body weight alone, 87 mg/kg body weight with pb). However, there were delayed toxic effects, including congestion and edema of the lungs, which are rarely seen after retrorsine /poisoning/.

In male rats, protection against acute deaths was given when mixed-function oxidases were inhibited by skf-525a (ip LD50's, 53 mg/kg body weight) and by a 4-day sucrose diet (ip LD50's, 120 mg/kg body weight), but chronic hepatic and pulmonary lesions developed subsequently.

Natural Pollution SourcesRETRORSINE IS A COMMON CONSTITUENT OF SENECIO ERUCAEFOLIUS, S JACOBAEA & S VULGARIS SPECIES.
Human Toxicity Excerpts · 5건

/HUMAN EXPOSURE STUDIES/ The two main sources of pyrrolizidine alkaloid poisoning reported in human beings are the consumption of cereal grain contaminated by weeds containing the alkaloids and the use of alkaloid-containing herbs for medicinal and dietary purposes. ...Three of the largest outbreaks of the disease have been reported from South Asia, two from the same site in central India and one from North-West Afghanistan. The first Indian outbreak... occurred in a group of 5 tribal villages in central India in 1972-73. ...Out of a total population of 2,060 in these villages, 71 households with 366 members were investigated. Among these, 39 cases had developed and 19 had died before commencement of the investigations. The incidence rate was 1.1% and the case fatality rate was 50%. All cases occurred among 20 households. In many households, several members were affected. In one household, 4 out of 5 cases died. ...The etiological factor of this outbreak was not established, though dietary contamination with pyrrolizidine alkaloids was considered. A second outbreak occurred at the same site in 1975... . A total population of 486 was affected, 67 cases were reported, of whom 28 (46%) had died. There was a strong family history... . In a later survey, 108 patients were studied and the mortality rate was estimated to be 63%. This time the etiological factor was identified as the plant Crotalaria nana Burm, which had been growing in the fields of millet (Panicum miliare), their staple food crop. The seeds of this plant became mixed with the cereal grain during harvesting. The toxic seeds contained pyrrolizidine alkaloids that were identified as a macrocyclic ester closely similar to monocrotaline. The total alkaloid content was estimated to be 5.3 g/kg of seed, expressed as monocrotaline. The levels of contamination of the millet with seeds were reported to be 0-3.4 g/kg in the unaffected and 0-19 g/kg in the affected households... . /Pyrrolizidine alkaloids/

/HUMAN EXPOSURE STUDIES/ The largest outbreak reported to date occurred in the Gulran district of Herat Province in northwest Afghanistan, close to the border of the USSR. ...The outbreak, was estimated to have affected a population of approximately 35,000 in 98 villages. Examination of 7,200 inhabitants of the affected villages showed evidence of disease in 22.6%, which was more serious in 15%. Thus, it was estimated that approximately 8,000 subjects suffered from the disease including 5,000 who were seriously affected. All age groups were affected, but 46% of subjects were below 14 years of age. However, no sign of disease was found in children below 2 years of age. A detailed report concerning the pathological material obtained from 14 liver biopsies and 8 autopsies was made... /although/ the time interval between the onset of symptoms and the biopsy/autopsy was not indicated. Pathological findings were characteristic, ranging from acute disease with characteristic veno-occlusion to non-portal cirrhosis, which was observed in 5 of the above 22 cases. The outbreak was ascribed to massive contamination of wheat, the staple food crop, following 2 years of drought, with the seeds of Heliotropium popovii H. Riedl subsp. gillianum H. Riedl, which had been growing profusely among the wheat crop. The seeds contained pyrrolizidine alkaloids at concentrations reported by 2 laboratories to be 7.2 and 13.2-14.9 g/kg, identified mainly as the N-oxide of heliotrine (74%)..., and one or two other compounds similar in character to lasiocarpine. Samples of wheat from several villages contained an average of 40 seeds/kg, i.e., 0.03% by weight. It was estimated that an adult consumed at least 700 g flour/day, containing approximately 2 mg alkaloid (based on a mean of the seed analyses). /Pyrrolizidine alkaloids/

/HUMAN EXPOSURE STUDIES/ Human consumption... occurs from Symphytum and Senecio species in some herbal preparations, such as "comfrey tea" or "groundsel tea". /Pyrrolizidine alkaloids from Senecio species/

/SIGNS AND SYMPTOMS/ Retrorsine is one of the main alkaloids present in the Senecio species which have contaminated grain in South Africa and so caused the often fatal 'bread poisoning' of humans in South Africa. The most common symptoms were severe abdominal pain, rapidly developing ascites and hepatomegaly. In some outbreaks there were extreme emaciation, nausea, and diarrhea.

For more Human Toxicity Excerpts (Complete) data for RETRORSINE (6 total), please visit the HSDB record page.

Carcinogen Classification · 5건

Retrorsine

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 10: (1976) Some Naturally Occurring Substances

1987

1987

Non-Human Toxicity Excerpts · 5건

/LABORATORY ANIMALS: Acute Exposure/ Administration of 40 mg/kg body weight retrorsine by stomach tube to rats caused a severe and rapid inhibition of the synthesis of liver and serum proteins.

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Suckling rats died with severe liver and other typical pyrrolizidine-induced lesions when their mothers were given 20-84 mg/animal retrorsine in doses of 5-10 mg orally or ip twice weekly or more often. The mothers survived, although liver lesions developed.

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Female Wistar rats with new-born litters were fed either control or a retrorsine (50 mg/kg) diet. At 0, 4, 8, 11, 15, 18 and 21 days, pups from each litter were weighed, sacrificed and their livers removed for copper, DNA and metallothionein analysis. Serum samples were assayed for caeruloplasmin oxidase activity and albumin. ... Retrorsine passing to rat neonates via breast milk causes: the accumulation, of hepatic copper, impairment of the rise in serum caeruloplasmin, which could indicate a decline in synthesis or failure of copper incorporation into the apo-protein, a decrease in hepatic metallothionein and serum albumin levels, again suggesting diminished protein synthesis, and reduced hepatic DNA indicative of decreased cell number but increased cell size. Accumulation of liver copper but reduction of copper-binding proteins could result in free copper and explain the synergistic hepatotoxicity of copper and retrorsine.

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Most studies have examined the effects in the liver; the tumors produced are mostly of epithelial origin, but a significant number are also vascular. Possible types of tumor include: hepatomas; hepatocellular carcinoma with metastases; mammary tumors; lung carcinoma; renal carcinomas; colonic carcinoma; splenic hemangioendothelioma; osteosarcoma bone; leukemia; 'spindle cell" tumor (neck); uterine carcinoma; retroperitoneal sarcoma; and squamous cell carcinoma (of the jaw) were described for retrorsine. /Pyrrolizidine alkaloids/

For more Non-Human Toxicity Excerpts (Complete) data for RETRORSINE (12 total), please visit the HSDB record page.

Evidence for CarcinogenicityNo data are available in humans. Limited evidence of carcinogenicity in animals. OVERALL EVALUATION: Group 3: The agent is not classifiable as to its carcinogenicity to humans.
Antidote and Emergency Treatment · 3건

Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poison A and B/

Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in respiratory arrest. Positive pressure ventilation techniques with a bag valve mask device may be beneficial. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of fluid overload. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poison A and B/

Presentation depends on the active toxic agent. In most cases, vomiting, abdominal pain, and diarrhea occur within 60 to 90 minutes of significant ingestion. With some toxins, severe gastroenteritis may result in massive fluid and electrolyte loss. ... Maintain open airway and assist ventilation if necessary. Administer supplemental oxygen. Treat coma, seizures, arrhythmias, and hypotension if they occur. Replace fluid loss caused by gastroenteritis with intravenous crystalloid solutions. ... Administer activated charcoal if available ... Gastric emptying is not necessary if activated charcoal is given promptly. /Plants and Herbal Medicines: Group 1/

Non-Human Toxicity Values · 3건

LD50 Mouse iv 59 mg/kg

LD50 Rat ip 34 mg/kg

LD50 Rat iv 38 mg/kg

안전 데이터

wgk
3
rtecs
VH7525000
ridadr
1544
risk_code
25
hazard_code
T
safety_code
22-36/37/39-45
포장분류
II
위험 등급
6.1(a)
Hazard Classifications
Acute Tox. 2 DermalAcute Tox. 2 InhalationAcute Tox. 2 Oral
스토리지 클래스
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
유해 물질 데이터
480-54-6(Hazardous Substances Data)
Metabolism/Metabolites · 5건

Studies with retrorsine have confirmed the formation of the n-oxide and pyrrolic metabolites /retrorsine pyrrole/ by the mixed-function oxidase system of the microsomal fraction of rat liver.

In animals, the major metabolic routes of pyrrolizidine alkaloids are: (a) hydrolysis of the ester groups; (b) N-oxidation; and (c) dehydrogenation of the pyrrolizidine nucleus to pyrrolic derivatives. Routes (a) and (b) are believed to be detoxification mechanisms. Route (c) leads to toxic metabolites. Route (a) occurs in liver and blood; routes (b) and (c) are brought about in the liver by the microsomal mixed function oxidase system. /pyrrolizidine alkaloids/

The in vivo metabolism and excretion of the urinary metabolites from the pyrrolizidine alkaloids (PAs), retrorsine (RET) and retrorsine-N-oxide (RET-NO) have been studied in rats. Isatinecic acid (INA), pyrrolic metabolites, N-oxides and retronecine accounted for 31.0, 10.3, 10.8 and 0.39% of the administered RET. Predosing rats with triorthocresyl phosphate (TOCP), had no effect on the excretion of pyrrolic metabolites and INA. Phenobarbital (PB) increased the excretion of both pyrrolic metabolites and INA with a corresponding decrease in the excretion of RET and N-oxides; the retronecin levels remained unaltered. When RET-NO was administered i.p., the urinary levels of pyrrolic metabolites, INA and RET were decreased relative to those treated with RET. The p.o. administration of RET-NO produced significantly higher levels of pyrrolic metabolites, INA and RET. These results suggest that esterase hydrolysis plays a minor role in the formation of INA and that a common metabolic pathway may exist between pyrrolic metabolites and INA formation.

...Retrorsine was administered to a cohort of young adult male rats and examined induction or enhanced expression of mRNA and protein for widely studied hepatic CYP isoforms spanning four families together with the essential enzyme CYP reductase. The protein levels of normally expressed CYPs 1A2, 2B1/2, and 2E1 increase significantly in rat liver microsomes from retrorsine-treated rats compared to untreated control rats (P< 0.05), but protein levels of CYP 4A3, CYP 3A1, and CYP reductase were unchanged after retrorsine treatment. In addition, CYP 1A1 mRNA and protein, which are not detectable in the livers of control rats, were induced after retrorsine exposure. The results of the present study demonstrate enhanced or induced expression of hepatic CYPs 1A1, 1A2, 2E1, and 2B1/2 in response to retrorsine exposure in rats, suggesting that one or more of these enzymes may be involved in retrorsine metabolism.

For more Metabolism/Metabolites (Complete) data for RETRORSINE (6 total), please visit the HSDB record page.

MeSH Pharmacological ClassificationAgents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Absorption, Distribution and Excretion · 2건

In animal studies highest concentrations were found in the liver, lungs, kidneys and spleen. /pyrrolizidine alkaloids/

When pyrrolizidine alkaloids, retrorsine 60 mg/kg, retrorsine n-oxide 60 mg/kg were administered ip to rats, 0.2-12.4% of the doses were excreted in the urine within 24 hr as metabolic pyrroles. There was a rough correlation between the hepatotoxicity of alkaloids and the amount of pyrroles to which they gave rise to in vivo. When rats were dosed orally or ip with retrorsine 50 mg/kg and sacrificed after various times, metabolic pyrroles were found bound strongly to the liver, and to /lesser/ extent the lung and other organs, for 48 hr or more after being formed.

용도 및 제조

Uses · 1건

Some of the Senecio species in which it occurs have been used as medicinal herbs; eg, S. discolor (SW)DC was used against coughs, colds, fevers and indigestion in Jamaica; S. bupleuroids DC was reported to be an ingredient in an African remedy for chest troubles; and S. vulgaris was used in Europe for dysmenorrhea and amenorrhea and in the U.S. as a diaphoretic, diuretic, tonic and emmenagogue. S isatideue is a high-yielding source suitable for preparative purposes.

Methods of Manufacturing... Not produced commercially.
General Manufacturing Information · 1건

Retrorsine is a common constituent of Senecio species (family Compositae) and has been isolated from S. ambrosioides, S. ampullaceus Hook., S. bupleuroides DC., S. discolor DC., S. douglassii DC., S. eremophilus Richards, S. glaberrimus DC., S. graminofolius N.J. Jacq., S. ilicifolius Thunb., S. isatideus DC., S. longilobus Benth., S. paucicalyculatus Klatt, S. pterophorus DC., S. quadridentatus Labill., S. retrorsus DC., S. riddellii Torr. et A. Gray var. parksii (Cory), S. ruderalis Harvey, S. sceleratus Schweickerdt, S. venosus Harvey, S. vulgaris L., S. bipinnatisectus Belcher, S. brasiliensis Less., S. grisebachii and S. swaziensis Compton. Retrorsine has also been isolated from Crotalaria usaramoensis E.G. Baker and C. spartioides DC. (family Leguminosae).

응용 분야 · 1건

일반 설명This substance is a primary reference substance with assigned absolute purity (considering chromatographic purity, water, residual solvents, inorganic impurities). The exact value can be found on the certificate. Produced by PhytoLab GmbH & Co. KG

공급사69 곳

南京世洲生物科技有限公司025-85560043 15850508050 · [email protected]
南通飞宇生物科技有限公司0513-68819626 15152877458 · [email protected]
成都乐美天医药科技有限公司17308096051 17308096051 · [email protected]
武汉英诺医药科技有限公司+86-027-59232304 15387063101 · [email protected]
成都彼样生物科技有限公司18108052721 · [email protected]
成都健腾生物技术有限公司028-85159085 18080455027 · [email protected]
武汉众志诚生物技术有限公司13628624121 13628604890 · [email protected]
上海纽雀客生物科技有限公司13916276291 · [email protected]
湖北丹鼎医药科技有限公司18917019315(微信同号) 17701422019 · [email protected]
大连美仑生物技术有限公司0411-62910999 13889544652 · [email protected]
安耐吉化学&3A(安徽泽升科技有限公司)021-58432009 400-005-6266 · [email protected]
梯希爱(上海)化工贸易有限公司021-61109150 · [email protected]
欧利希(湖北)医药科技有限公司17316404525 17316404525 · [email protected]
上海诗丹德标准技术服务有限公司021-021-57127007-6622-6622 17621252073 · [email protected]
成都普思生物科技股份有限公司028-85370565-229 18080489829 · [email protected]
怀化市冰峰化工有限公司0745-2866851 17711757908 · [email protected]
上海相辉医药科技有限公司13761987713; 13761987713 · [email protected]
武汉丰泰威远科技有限公司+86-27-8746-5837 +86-18627785180 · [email protected]
武汉市皇臻生物化工有限公司13795480948 · [email protected]
武汉丰泰威远科技有限公司027-87465837 19945049750 · [email protected]
Chengdu Youngshe Chemical Co., Ltd.+86-18108235634 · [email protected]
佛山宝诺生物科技有限公司0757-85921206 18520245316 · [email protected]
Aktin Chemicals, Inc.028-85159085 · [email protected]
TargetMol 中国(陶术生物)400-821-0310 15002144251 · [email protected]
成都思天德生物科技有限公司028-83243028 19136088901 · [email protected]
深圳振强药物研发有限公司0755-66853366 13670046396 · [email protected]
雷丁试剂0510-85629785 18013409632 · [email protected]
天津普西唐生物医药科技有限公司010-60605840 · [email protected]
凯试(上海)科技有限公司021-50135380 · [email protected]
Sigma-Aldrich西格玛奥德里奇(上海)贸易有限公司021-61415566 800-8193336 · [email protected]
ALB Technology Limited702-983-3769 · [email protected]
武汉天植生物技术有限公司18607101326 15172504745 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
四川精萃天成药物科技有限公司028-87865381 18108190480 · [email protected]
碧语生物科技(上海)有限公司021-26018599
上海谱振生物科技有限公司4001650900 13817534909 · [email protected]
浙江珲达生物科技有限公司0571-89903022 18679456698 · [email protected]
风咏生物(AbMole)021-10000000 13000000000 · [email protected]
EMMX Biotechnology LLC888-539-0666 · [email protected]
上海源叶生物科技有限公司18916372613 · [email protected]
武汉沃格达生物科技有限公司15071299552 · [email protected]
BOC Sciences[email protected]
Shanghai Acmec Biochemical Technology Co., Ltd.+86-18621343501 · [email protected]
Shaanxi Didu New Materials Co. Ltd+86-86-17392712779 +86-13289823923 · [email protected]
深圳市丽晶生化科技有限公司0755-85201366 18938635012 · [email protected]
成都格纯生物医药有限公司028-88203606 18881370802 · [email protected]
北京沃凯生物科技有限公司010-62971590 18548936886 · [email protected]
成都格纯生物医药有限公司18283602253 · [email protected]
南京狄尔格医药科技有限公司025-025-51191215 18013836722 · [email protected]
合肥博美生物科技有限责任公司13739298932 13856598764 · [email protected]